Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Sintx Technologies (SINT) Short-Term Debt repayments (2013)

Sintx Technologies' quarterly Short-Term Debt repayments came in at $5.1 million in Q3 2013, up 89.95% quarter-over-quarter from $2.7 million in Q2 2013.

Sintx Technologies has reported Short-Term Debt repayments for 1 years, with the latest figure at $5.1 million in Q3 2013.

  • For the quarter ending Q3 2013, Short-Term Debt repayments changed N/A year-over-year to $5.1 million; the trailing twelve-month figure through Dec 2013 stood at $13.5 million (changed N/A YoY), and the FY2013 full-year result was $13.5 million, changed N/A from the prior year.
  • Short-Term Debt repayments for Q3 2013 stood at $5.1 million, up from $2.7 million in the prior quarter.
  • The five-year high for Short-Term Debt repayments was $5.7 million in Q1 2013, with the low at $2.7 million in Q2 2013.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Short-Term Debt repayments (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 259.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Sintx Technologies 8.71 Mn 6.82 Mn 144,000.00 -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2013 5.12 Mn
Sep 30, 2013 5.12 Mn
Jun 30, 2013 2.70 Mn
Jun 30, 2013 2.70 Mn
Mar 31, 2013 5.70 Mn
Mar 31, 2013 5.70 Mn